nasr, fadi hôtel-dieu de france-university medical center(umc) - mount lebanon hospital, lebanese hospital geitaoui-umc - oncology and hematology department, Beirut, lebanon , sadek, maroun lebanese university - faculty of medical sciences - oncology and hematology department, Beirut, Lebanon

A CASE OF NON-SMALL CELL LUNG CANCER TREATED WITH OSIMERTINIB

18434

Background : Recent clinical trials have proven the clinically significant efficacy and tolerability of osimertinib (Tagrissoâ), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and EGFR with the T790M resistance mutation in patients with with non-small cell lung cancer (NSCLC). Case présentation : Hereby, we present the case of a 54-year-old patient with stage IV lung cancer who progressed after initiation of a second generation of EGFR TKIs (Gefitinib), a T790M mutation was detected. The patient was started on osimertinib (Tagrissoâ) with favorable outcomes. Conclusion :We do believe that physicians should be made aware that, in patients with NSCLC who progress on EGFRTKIs, searching for T790M mutation is mandatory.

297

non , small cell lung cancer (NSCLC) , osimertinib , T790M mutation , epidermal growth factor receptor , tyrosinekinase inhibitors (EGFR , TKI)

Lebanese Medical Journal

299